In vitro preclinical testing of nonoxynol-9 as potential anti-human immunodeficiency virus microbicide: a retrospective analysis of results from five laboratories.

From:
Department for International Development
Published
1 January 2006
Document Type:
Journal Article
Theme:
Health
Authors:
Watson, K., Shattock, R.J., Fletcher, P.S., Beer, B.E., Doncel, G.F., Krebs, F.C., Dezzutti, C.S., Cummins, J.E., Bromley, E., Richardson-Harman, N., Pallansch, L.A., Lackman-Smith, C., Osterling, C., Mankowski, M., Miller, S.R., Catalone, B.J., Welsh, P.A., Howett, M.K., Wigdahl, B., Turpin, J.A., Reichelderfer, P., Buckheit, R.W., Jr.

Abstract

The first product to be clinically evaluated as a microbicide contained the nonionic surfactant nonoxynol-9 (nonylphenoxypolyethoxyethanol; N-9). Many laboratories have used N-9 as a control compound for microbicide assays. However, no published comparisons of the results among laboratories or attempts to establish standardized protocols for preclinical testing of microbicides have been performed. In this study, we compared results from 127 N-9 toxicity and 72 efficacy assays that were generated in five different laboratories over the last six years and were performed with 14 different cell lines or tissues. Intra-assay reproducibility was measured at two-, three-, and fivefold differences using standard deviations. Interassay reproducibility was assessed using general linear models, and interaction between variables was studied using step-wise regression. The intra-assay reproducibility within the same N-9 concentration, cell type, assay duration, and laboratory was consistent at the twofold level of standard deviations. For interassay reproducibility, cell line, duration of assay, and N-9 concentration were all significant sources of variability (P 24 h) and short (

Citation

Antimicrob Agents and Chemotherapy (2006) 50 (2) pp. 713-723 [doi:10.1128/AAC.50.2.713-723.2006].

Published 1 January 2006
Contents